Maximum Matching in Turnstile Streams

We consider the unweighted bipartite maximum matching problem in the one-pass turnstile streaming model where the input stream consists of edge insertions and deletions. In the insertion-only model, a one-pass $2$-approximation streaming algorithm can be easily obtained with space $O(n \log n)$, where $n$ denotes the number of vertices of the input graph. We show that no such result is possible if edge deletions are allowed, even if space $O(n^{3/2-\delta})$ is granted, for every $\delta > 0$. Specifically, for every $0 \le \epsilon \le 1$, we show that in the one-pass turnstile streaming model, in order to compute a $O(n^{\epsilon})$-approximation, space $\Omega(n^{3/2 - 4\epsilon})$ is required for constant error randomized algorithms, and, up to logarithmic factors, space $O( n^{2-2\epsilon} )$ is sufficient. Our lower bound result is proved in the simultaneous message model of communication and may be of independent interest

Passatempo Virus, a Vaccinia Virus Strain, Brazil

Passatempo virus was isolated during a zoonotic outbreak. Biologic features and molecular characterization of hemagglutinin, thymidine kinase, and vaccinia growth factor genes suggested a vaccinia virus infection, which strengthens the idea of the reemergence and circulation of vaccinia virus in Brazil. Molecular polymorphisms indicated that Passatempo virus is a different isolate

Large-eddy simulation of low-frequency unsteadiness in a turbulent shock-induced separation bubble

The need for better understanding of the low-frequency unsteadiness observed in shock wave/turbulent boundary layer interactions has been driving research in this area for several decades. We present here a large-eddy simulation investigation of the interaction between an impinging oblique shock and a Mach 2.3 turbulent boundary layer. Contrary to past large-eddy simulation investigations on shock/turbulent boundary layer interactions, we have used an inflow technique which does not introduce any energetically significant low frequencies into the domain, hence avoiding possible interference with the shock/boundary layer interaction system. The large-eddy simulation has been run for much longer times than previous computational studies making a Fourier analysis of the low frequency possible. The broadband and energetic low-frequency component found in the interaction is in excellent agreement with the experimental findings. Furthermore, a linear stability analysis of the mean flow was performed and a stationary unstable global mode was found. The long-run large-eddy simulation data were analyzed and a phase change in the wall pressure fluctuations was related to the global-mode structure, leading to a possible driving mechanism for the observed low-frequency motions

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

The identification of lymphoid cell subpopulations in sections of human lymphoid tissue and gingivitis in children using monoclonal antibodies

Monoclonal antibodies made against lymphocyte differentiation antigens were used to characterize phenotypically the lymphoid cell subpopulations in sections of human lymphoid tissue and inflamed gingival tissue associated with the deciduous dentition in children. Four monoclonal antibodies designated FMC 1, FMC 4, FMC 7, and UCHT1 were used. These antibodies are specific for B‐cells, p28,33 (la‐like) antigen, a B‐cell subset, and peripheral T‐cells respectively. FMC 1 and FMC 4 positive cells (B‐cells) were found mainly in the secondary follicles while UCHT1 positive cells (T‐cells) were found in the parafollicular areas of human tonsils. Cells in some, but not all, secondary follicles in the tonsils were FMC 7 positive. In the gingival tissue only 12.6 % of the infiltrating cells were FMC 1 positive, 12.2 % were FMC 4 positive, and 4.8 % FMC 7 positive. On the other hand over 75 % of cells appeared to be UCHT1 positive. These results indicate that the majority of inflammatory cells in gingivitis associated with the deciduous dentition in children have the phenotype B‐cell antigen‐/p28,33 (lalike) antigen‐/B‐cell subset antigen‐ and possibly T‐cell antigen+. Such a phenotype is, at least by exclusion, suggestive of T‐cells and as such confirms earlier studies using T‐cell enzyme markers. Copyrigh